• Libido and sexual function: low libido or erectile difficulties.
• Energy and stamina: fatigue or reduced physical drive.
• Mood changes: low mood, irritability or reduced motivation.
• Body composition: weight gain or increased central adiposity.
• Muscle health: loss of muscle mass or reduced strength.
• Sleep disturbances: poor sleep quality or disrupted sleep patterns.
• Metabolic concerns: adverse changes in blood lipid markers or metabolic features.
• Bone health concerns: reduced bone density or fracture risk indicators.
• Androgen-related symptoms: features associated with low testosterone levels.
• Thyroid-related symptoms: low stamina, fatigue or feeling cold.

Comprehensive Male II measures four-point salivary cortisol alongside dried blood spot oestradiol, testosterone, DHEA-S, sex hormone binding globulin, prostate-specific antigen, thyroid stimulating hormone, free T3, free T4 and thyroid peroxidase antibodies. This combination brings together adrenal, testicular and thyroid hormone markers within a single assessment.

This test may be clinically useful when hormone-related symptoms span energy, mood, sexual function, sleep, body composition or metabolic concerns. Assessing these hormone groups together allows practitioners to observe how adrenal, thyroid and sex hormone markers align, rather than considering each system in isolation.

Practitioners typically interpret results alongside age, life stage, stress exposure, medication or hormone use, diet, physical activity and other laboratory findings. This integrated approach supports informed discussions with clients about hormone-related patterns and day-to-day health experiences.

Practical

Specimen requirements:

Saliva + Dried bloodspot (DBS)

Average processing time:

14 ±6 days

Research

• Araujo AB, O’Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM,McKinlay JB. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004;89:5920-6.

• Carruba G. Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario. J Cell Biochem. 2007;102:899-911.

• Elmlinger MW, Dengler T, Weinstock C, Kuehnel W. Endocrine alterations in the aging male. Clin Chem Lab Med. 2003;41:934-41.

• Endogenous Hormones, Prostate Cancer Collaborative Group, Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008;100:170-83.

• Magri F, Cravello L, Barili L, Sarra S, Cinchetti W, Salmoiraghi F, Micale G, Ferrari E. Stress and dementia: the role of the hypothalamic-pituitary-adrenal axis. Aging Clin Exp Res. 2006;18(2):167-70.

• Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60:762-9.

• Risbridger GP, Bianco JJ, Ellem SJ, McPherson SJ. Oestrogens and prostate cancer. Endocr Relat Cancer. 2003;10:187-91.

• Risbridger GP, Ellem SJ, McPherson SJ. Estrogen action on the prostate gland: a critical mix of endocrine and paracrine signaling. J Mol Endocrinol. 2007;39:183-8.

• Selby C. Sex hormone binding globulin: origin, function and clinical significance. Ann Clin Biochem. 1990;27:532-41.

• Tindall DJ, Rittmaster RS. The rationale for inhibiting 5alphareductase isoenzymes in the prevention and treatment of prostate cancer. J Urol. 2008;179:1235-42.